Townsquare Capital LLC Has $432,000 Stock Holdings in Smith & Nephew plc (NYSE:SNN)

Townsquare Capital LLC boosted its position in shares of Smith & Nephew plc (NYSE:SNN) by 19.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,557 shares of the medical equipment provider’s stock after acquiring an additional 2,798 shares during the period. Townsquare Capital LLC’s holdings in Smith & Nephew were worth $432,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of SNN. River Road Asset Management LLC raised its stake in shares of Smith & Nephew by 64.0% in the fourth quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider’s stock valued at $49,947,000 after purchasing an additional 792,829 shares in the last quarter. Raymond James Financial Inc. bought a new stake in Smith & Nephew in the 4th quarter valued at $4,992,000. ABC Arbitrage SA acquired a new position in shares of Smith & Nephew in the 4th quarter valued at $4,847,000. Brandes Investment Partners LP lifted its holdings in shares of Smith & Nephew by 11.4% during the 4th quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider’s stock worth $33,504,000 after acquiring an additional 138,994 shares during the period. Finally, Clark Estates Inc. NY boosted its position in shares of Smith & Nephew by 16.8% during the 4th quarter. Clark Estates Inc. NY now owns 800,000 shares of the medical equipment provider’s stock valued at $19,664,000 after acquiring an additional 115,000 shares in the last quarter. Institutional investors own 25.64% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. StockNews.com upgraded shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 26th. UBS Group downgraded Smith & Nephew from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 12th. Finally, Canaccord Genuity Group reiterated a “hold” rating and set a $27.00 price objective on shares of Smith & Nephew in a research note on Monday, March 17th. Four research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $27.00.

Smith & Nephew Stock Up 0.8 %

Shares of SNN opened at $25.90 on Monday. The business’s 50 day simple moving average is $27.45 and its 200-day simple moving average is $26.41. Smith & Nephew plc has a one year low of $23.69 and a one year high of $31.72. The company has a market capitalization of $11.32 billion, a P/E ratio of 11.99, a PEG ratio of 1.26 and a beta of 0.71. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Increases Dividend

The firm also recently announced a semi-annual dividend, which will be paid on Wednesday, May 28th. Stockholders of record on Friday, March 28th will be paid a $0.447 dividend. The ex-dividend date of this dividend is Friday, March 28th. This is a positive change from Smith & Nephew’s previous semi-annual dividend of $0.29. This represents a dividend yield of 2.5%. Smith & Nephew’s dividend payout ratio (DPR) is 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.